Presentation and Publication
The titles and presenting authors of all regular abstracts scheduled for presentation at this conference are available at the following links:
With the exception of abstracts selected for the conference press program, all conference abstracts will not be available until the Conference App is released on September 16, at 4:00 pm ET.
Download the CrowdCompass AttendeeHub App from the Apple Store or Google Play Store. Open the app, search for “Cancer Immunotherapy Conference” and follow the prompts to create a login. To use the online version of the app please click here.
Abstracts will be available online as a supplement to the AACR journal, Cancer Immunology Research, within 2-3 months of the conference. Every effort will be made to reproduce the content of the abstracts as submitted, except in certain circumstances where changes may be made to comply with the conference style guide.
Poster boards will be 4 feet high and 6 feet across. The organizers will provide poster numbers and pushpins.
From the accepted posters, a small number of highly rated abstract authors were also invited to deliver proffered short oral presentations of their work during the general sessions.
Presenting Authors must register for the conference and attend the session in which the abstract is scheduled to discuss the research in detail, according to the specific guidelines of the session. If an abstract is not accepted, the presenter may request a full refund of the registration fee.
Request for Withdrawal
Once an abstract has been submitted, it may be withdrawn only by written request from the Submitting Author. The request may be sent by email to email@example.com and must be received at least 30 days prior to the start of the conference.
If due to unforeseen circumstances the designated Presenting Author is unavailable to attend the session to present the abstract, the Submitting Author must contact firstname.lastname@example.org to designate a co-author to serve as the Presenting Author. If no authors are available to present the abstract, the Submitting Author must withdraw the abstract immediately by emailing email@example.com
Clinical Trials of Cancer Immunotherapies
Convergence of Technology and Cancer Immunotherapy
Genetically Engineered T Cells
Maintenance of Immune Balance: Effects of Targeted and Immune Therapies
Microbiome and Metabolism
Mutational Analysis and Predicting Response to Immunotherapy
Novel Vaccine Platforms and Combinations
Regulating T Cells and Their Response to Cancer
Tackling the Tumor Microenvironment - Beyond T Cells
Trials in Progress